Abstract
Promiscuous binding has been considered to be a problem in the design and development of new drugs against a given disease. However, promiscuity in molecular recognition is not all bad news, and scientists are currently taking advantage of the emerging 'promiscuous binding' or 'multi-target approach' in medicinal chemistry.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 896-897 |
| Number of pages | 2 |
| Journal | Bioorganic and Medicinal Chemistry |
| Volume | 14 |
| Issue number | 4 |
| DOIs | |
| State | Published - Feb 15 2006 |
Bibliographical note
Funding Information:The author thanks the referees for their useful comments and suggestions, and Asya Varbanova for the review of the manuscript draft. The author’s research is supported by a research stipend granted by the Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota.
Keywords
- Alzheimer's disease
- Cancer
- Drug design
- Promiscuous drug
